Achieve Life Sciences (ACHV) Resumen de Acciones
Achieve Life Sciences, Inc. es una empresa farmacéutica en fase avanzada que desarrolla y comercializa citisiniclina para la independencia de la nicotina en Canadá, Estados Unidos y Reino Unido. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 2/6 |
| Crecimiento futuro | 5/6 |
| Rendimiento pasado | 0/6 |
| Salud financiera | 1/6 |
| Dividendos | 0/6 |
Recompensas
Análisis de riesgos
ACHV Community Fair Values
Create NarrativeSee what 32 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Competidores de Achieve Life Sciences, Inc.
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | US$7.59 |
| Máximo en las últimas 52 semanas | US$7.60 |
| Mínimo de 52 semanas | US$2.46 |
| Beta | 2.23 |
| Cambio en 1 mes | 19.91% |
| Variación en 3 meses | 43.48% |
| Cambio de 1 año | 197.65% |
| Variación en 3 años | 54.90% |
| Variación en 5 años | 9.84% |
| Variación desde la OPV | -99.14% |
Noticias y actualizaciones recientes
ACHV: FDA Resubmission And Potential First New Cessation Therapy Could Reignite Upside
Analysts have lowered the fair value estimate for Achieve Life Sciences from $15.38 to $13.80, while still highlighting Street research that points to a $20 price target, supported by expectations around cytisinicline's Phase 2b and Phase 3 data and its potential role as a first new FDA-approved smoking cessation therapy in roughly 20 years. What’s in the News for Achieve Life Sciences Stockholders approved an amendment to Achieve Life Sciences' Certificate of Incorporation at the July 2, 2026 annual meeting, increasing authorized common shares from 150,000,000 to 300,000,000.
ACHV: FDA Response And Index Inclusion Will Shape Smoking Cessation Outlook
Analysts have trimmed their fair value estimate for Achieve Life Sciences from $10.00 to $9.00, citing updated price target work that balances higher modeled revenue growth, improved profit margins, and a slightly lower discount rate against more conservative future P/E assumptions. Analyst Commentary on Achieve Life Sciences Recent Street research on Achieve Life Sciences highlights a mix of optimism around its cytisinicline program and more cautious views tied to execution, regulatory timing, and market adoption.
ACHV: Manufacturing Progress And Margin Potential Will Support Bullish Thesis
Analysts have reset their 12 month price target on Achieve Life Sciences to $21 from $25, citing updated views on future valuation multiples, margin potential and revenue ramp outlined in recent bullish research coverage. Analyst Commentary Recent Street research on Achieve Life Sciences points to a cluster of bullish views that frame the updated US$21, 12 month price target as part of a broader constructive stance on the stock.Recent updates
ACHV: FDA Resubmission And Potential First New Cessation Therapy Could Reignite Upside
Analysts have lowered the fair value estimate for Achieve Life Sciences from $15.38 to $13.80, while still highlighting Street research that points to a $20 price target, supported by expectations around cytisinicline's Phase 2b and Phase 3 data and its potential role as a first new FDA-approved smoking cessation therapy in roughly 20 years. What’s in the News for Achieve Life Sciences Stockholders approved an amendment to Achieve Life Sciences' Certificate of Incorporation at the July 2, 2026 annual meeting, increasing authorized common shares from 150,000,000 to 300,000,000.ACHV: FDA Response And Index Inclusion Will Shape Smoking Cessation Outlook
Analysts have trimmed their fair value estimate for Achieve Life Sciences from $10.00 to $9.00, citing updated price target work that balances higher modeled revenue growth, improved profit margins, and a slightly lower discount rate against more conservative future P/E assumptions. Analyst Commentary on Achieve Life Sciences Recent Street research on Achieve Life Sciences highlights a mix of optimism around its cytisinicline program and more cautious views tied to execution, regulatory timing, and market adoption.ACHV: Manufacturing Progress And Margin Potential Will Support Bullish Thesis
Analysts have reset their 12 month price target on Achieve Life Sciences to $21 from $25, citing updated views on future valuation multiples, margin potential and revenue ramp outlined in recent bullish research coverage. Analyst Commentary Recent Street research on Achieve Life Sciences points to a cluster of bullish views that frame the updated US$21, 12 month price target as part of a broader constructive stance on the stock.Regulatory And Commercial Hurdles Will Test Smoking Cessation Catalyst Yet Long Term Potential Remains
Catalysts About Achieve Life Sciences Achieve Life Sciences is a biopharmaceutical company focused on bringing cytisinicline, a nicotine dependence treatment, to market for smoking and vaping cessation. What are the underlying business or industry changes driving this perspective?Regulatory Tailwinds And Public Health Demand Will Support This Nicotine Cessation Opportunity
Catalysts About Achieve Life Sciences Achieve Life Sciences is a clinical stage biopharmaceutical company focused on developing cytisinicline as a treatment for nicotine dependence in smokers and vapers. What are the underlying business or industry changes driving this perspective?FDA Priority Voucher And Smoking Cessation Tailwinds Will Transform This Undervalued Biotech Story
Catalysts About Achieve Life Sciences Achieve Life Sciences is a biopharmaceutical company focused on developing and commercializing cytisinicline as a treatment for nicotine dependence in smokers and people who vape. What are the underlying business or industry changes driving this perspective?Achieve Life Sciences: Could Be The Best 'Tobacco' Stock For 2026 - Strong Buy
Summary Achieve Life Sciences is a late-stage Pharma company awaiting FDA approval for Cytisinicline, a novel (though proven) smoking cessation therapy, with a decision expected in June. Cytisinicline demonstrates superior efficacy and safety versus current treatments, with strong precedent in Europe and a large, underserved U.S. market. ACHV’s market cap (~$250M) is a fraction of its potential, with peak sales for smoking and vaping cessation possibly reaching $2–3 billion. I rate ACHV a strong buy, citing favorable approval odds and blockbuster potential, but note dilution and supply chain risks. Read the full article on Seeking AlphaIs Achieve Life Sciences (NASDAQ:ACHV) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Rentabilidad de los accionistas
| ACHV | US Biotechs | Mercado US | |
|---|---|---|---|
| 7D | 14.1% | 0.5% | 0.6% |
| 1Y | 197.6% | 35.4% | 19.9% |
Rentabilidad vs. Industria: ACHV superó a la industria US Biotechs, que obtuvo un rendimiento del 35.4% el año pasado.
Rentabilidad vs. Mercado: ACHV superó al mercado US, que obtuvo un rendimiento del 19.9% el año pasado.
Volatilidad de los precios
| ACHV volatility | |
|---|---|
| ACHV Average Weekly Movement | 9.5% |
| Biotechs Industry Average Movement | 10.0% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Precio estable de las acciones: ACHV no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado US.
Volatilidad a lo largo del tiempo: La volatilidad semanal de ACHV (9%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| n/a | 28 | Andrew Goldberg | www.achievelifesciences.com |
Achieve Life Sciences, Inc, una empresa farmacéutica en fase avanzada, desarrolla y comercializa citisiniclina para la independencia de la nicotina en Canadá, Estados Unidos y Reino Unido. La empresa ofrece citisiniclina, un alcaloide natural que interactúa con los receptores de nicotina en el cerebro y reduce la gravedad de los síntomas de abstinencia de la nicotina. Tiene acuerdos de licencia y suministro con Sopharma AD y la Universidad de Bristol.
Resumen de fundamentos de Achieve Life Sciences, Inc.
| Estadísticas fundamentales de ACHV | |
|---|---|
| Capitalización bursátil | US$746.04m |
| Beneficios(TTM) | -US$114.04m |
| Ingresos (TTM) | n/a |
¿Está ACHV sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de ACHV | |
|---|---|
| Ingresos | US$0 |
| Coste de los ingresos | US$0 |
| Beneficio bruto | US$0 |
| Otros gastos | US$114.04m |
| Beneficios | -US$114.04m |
Últimos beneficios comunicados
Jun 30, 2026
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -1.11 |
| Margen bruto | 0.00% |
| Margen de beneficio neto | 0.00% |
| Ratio deuda/patrimonio | -101.6% |
¿Cómo se ha desempeñado ACHV a largo plazo?
Ver rendimiento histórico y comparativaAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/08/14 12:32 |
| Precio de las acciones al final del día | 2026/08/14 00:00 |
| Beneficios | 2026/06/30 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Achieve Life Sciences, Inc. está cubierta por 15 analistas. 11 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Gary Nachman | Canaccord Genuity |
| null null | CG Capital |
| Gary Nachman | CGS International |